key: cord-0270482-2yyk9d5k
authors: Lanskey, J. H.; Kocagoncu, E.; Quinn, A. J.; Cheng, Y.-J.; Karadag, M.; Pitt, J.; Isaac, J.; Lowe, S.; Perkinton, M.; Raymont, V.; Singh, K. D.; Woolrich, M.; Nobre, A. C.; Henson, R. N.; Rowe, J. B.
title: The New Therapeutics in Alzheimer's Disease Longitudinal Cohort study (NTAD): study protocol
date: 2021-05-18
journal: nan
DOI: 10.1101/2021.05.18.21257340
sha: d9526ccbde5b687edb49fb1757cff96f9b2536d5
doc_id: 270482
cord_uid: 2yyk9d5k

Introduction With the pressing need to develop treatments that slow or stop the progression of Alzheimer's disease, new tools are needed to reduce clinical trial duration and validate new targets for human therapeutics. Such tools could be derived from neurophysiological measurements of disease. Methods and Analysis The New Therapeutics in Alzheimer's disease study (NTAD) aims to identify a biomarker set from magneto/electro-encephalographic that is sensitive to disease and progression over one year. The study will recruit 100 people with amyloid-positive mild cognitive impairment or early-stage Alzheimer's disease and 30 healthy controls aged between 50 and 85 years. Repeat measurements of the clinical, cognitive and imaging data (magnetoencephalography, electroencephalography and magnetic resonance imaging) of participants with Alzheimer's disease or mild cognitive impairment will be taken at baseline and at one year. To assess reliability of magneto/electro-encephalographic changes, a subset of 30 participants with mild cognitive impairment or early-stage Alzheimer's disease will undergo repeat magneto/electro-encephalographic two weeks after baseline. Clinical and cognitive assessment will be repeated at 2 years. Linear mixed models of baseline and longitudinal change in neurophysiology are the primary analyses of interest, supported by Bayesian inference. Additional outputs will include relative effect sizes for physiological markers, atrophy and cognitive change and the respective numbers needed to treat each arm of simulated clinical trials of a future disease modifying therapy. Ethics and dissemination The study has received a favourable opinion from the East of England Cambridge Central Research Ethics Committee (REC reference 18/EE/0042). Results will be disseminated through internal reports, peer-reviewed scientific journals, conference presentations, website publication, submission to regulatory authorities and other publications. Data will be made available via the Dementias Platform UK Data Portal on completion of initial analyses by the NTAD study group.

• NTAD is a longitudinal, multicentre study of magneto/electro-encephalographic measures of Alzheimer's disease progression • NTAD assesses the test-retest reliability of magneto/electro-encephalographic parameters • All participants with early-stage Alzheimer's disease or mild cognitive impairment will be amyloid-positive

• Attrition during follow up may limit inferences • Recruitment is from volunteer panels and clinical services that may not reflect national diversity of people affected by Alzheimer's disease . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

With 44 million people living worldwide with dementia, treatments to slow or stop disease progression are urgently needed. Alzheimer's disease is the most prevalent dementia but despite rapid advances in therapeutics within preclinical models, [1, 2] clinical trials remain expensive, slow and challenging [3] [4] [5] with high-profile failures. [6] Significant bottlenecks exist in early-phase trials, where efficacy rates are very low and costs rapidly escalate. To bridge the gap between animal models and the human disease, better tools are needed to quantify pathogenic and pathophysiological mechanisms in patients, in vivo providing evidence to pursue or discontinue trials of a candidate treatment. These tools should be safe, scalable and able to support early-phase trials over a short duration and viable budget.

Brain imaging is widely used to diagnose dementia and measure pathology in clinical trials. There are diverse imaging methods with differential sensitivity to brain structure, chemistry, pathology and function. For example, magnetic resonance imaging (MRI) is commonly used to measure structural changes related to Alzheimer's disease, [7] such as entorhinal cortex [8] and hippocampus volumes. [9] Positron emission tomography (PET) can quantify and localise Alzheimer pathology, through the use of ligands that bind to the aggregated tau protein, [10] [11] [12] [13] [14] beta-amyloid plaques [15] and neuroinflammation. [16] The loss of synapses and synaptic plasticity is an early feature of Alzheimer's disease. [17] [18] [19] Indeed, measures of synaptic loss may be more sensitive than measures of atrophy to cognitive decline. [20, 21] As synaptic changes occur early in Alzheimer's disease, [20] such measures could be sensitive to the earliest precursors of cognitive involvement. This accords with preclinical models in transgenic mice where network physiology and cognition are impaired before tangles or cell death. [22] In contrast to preclinical models and post-mortem analysis, there are limited options to assess synaptic function in humans, in vivo. While PET imaging now offers ligands that indirectly quantify synaptic density, electroencephalography (EEG) and magnetoencephalography (MEG) measure neurophysiological properties that depend on synaptic integrity and function within local and large-scale brain networks. MEG can identify synaptic and local circuit impairments [23, 24] and their impact on network dynamics in Alzheimer's Disease, [25] [26] [27] [28] frontotemporal dementia, [24, [29] [30] [31] [32] and Lewy-body disease. [33] MEG and EEG therefore have potential to support and de-risk clinical trials of novel compounds. However, to enable MEG as a viable biomarker in clinical trials, one must assess longitudinal MEG and testretest reliability and harmonise MEG protocols across sites.

The New Therapeutics for Alzheimer's Disease (NTAD) study aims to identify viable MEG and EEG biomarkers for clinical trials. The NTAD consortium is a multicentre study established by the Dementias Platform UK and supported by the Medical Research Council, Alzheimer's Research UK and industry partners. trials. The sensitivity to disease progression should ideally also outperform current widely used biomarkers such as MRI and cognitive tests.

Our secondary objective is to identify a biomarker set that can predict disease progression, explaining individual differences in the future trajectory of disease (i.e. prognostic from baseline) and the variation in cognitive decline over time (i.e. mediating mechanisms).

The analysis of MEG parameters will occur in two stages. Stage 1 analyses will identify baseline, disease-sensitive MEG parameters and assess their reliability using test-retest data. Stage 2 analyses will assess the sensitivity of these parameters to longitudinal change.

Stage 1 analyses will assess the sensitivity of the cross-sectional MEG parameters to group effects (using parametric or non-parametric frequentist tests and receiver operating characteristic analyses and their Bayesian analogues), their correlation to baseline cognition (using Pearson or Spearman's rank correlation coefficient analyses) and their test-retest reliability (using intraclass correlation coefficient analyses). Stage 2 longitudinal analyses will assess how these neurophysiological markers change over ~12 months (using linear mixed models of change) and compare their sensitivity (as accuracy and effects sizes) to disease progression with MRI and cognitive measures. Using multiple regression models, we will identify baseline biomarkers that are predictive of disease progression. Post-hoc exploratory analyses will examine the relationship between cognitive and imaging biomarkers as a function of: (i) variations in tau haplotype, (ii) polymorphisms of genes related to plasticity (e.g. brain-derived neurotrophic factor), (iii) Alzheimer's disease risk alleles (e.g. apolipoprotein e4), (iv) polygenic risk scores of Alzheimer's disease, and (v) plasma tau levels.

This is a repeated-measures, observational-design study with 130 participants tested at two sites: Cambridge University and Oxford University. The protocol includes two stages ( Figure  1 ). The first, cross-sectional stage consists of baseline and test-retest sessions. Baseline sessions are comprised of clinical and neuropsychological assessments, an MRI scan and a MEG combined with EEG (M/EEG) scan. For the test-retest session, a subset of patients returns for a second M/EEG scan approximately two weeks after the first. Stage 2, at 12months, repeats baseline sessions, followed by a 24-month clinical and neuropsychological reassessment of patients.

Participants will be aged between 50 and 85 years, with similar numbers of men and women, with symptomatic mild cognitive impairment or Alzheimer's Disease (n=100) or normal cognition (n=30, Figure 1 ). Potential participants are identified using local registry data, regional memory clinics and Join Dementia Research. People completing other observational studies may also be invited to screening.

A participant information sheet detailing the study procedures is provided to candidate participants and a study partner (their 'informant'). The informant is someone who regularly sees the participant and is willing to attend and complete the assessments. Candidate participants are invited to a screening appointment where any further questions they may have are answered before they provide written, informed consent. The screening appointment allows further assessment of eligibility according to inclusion and exclusion criteria (Table  1) . Eligible people proceed to Stage 1.

. CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted May 18, 2021. ; is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted May 18, 2021. ; is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted May 18, 2021. ; https://doi.org/10.1101/2021.05.18.21257340 doi: medRxiv preprint

With power of 80% and =0.05, a one-tailed test of the cross-sectional NTAD data should detect (i) medium, group-wise effect sizes of >0.5 and (ii) correlations with disease severity of >0.25. With 20% attrition in follow up and =0.05, within-sample effect size >0.28 achieves power 80% ( Figure 2 ). [34] STUDY PROCEDURES

Screening Potential participants are identified by electronically screening registry data from Join Dementia Research and regional memory clinics. Prospective participants are screened further on-site. After written, informed consent, a doctor administers the clinical interview and Haschinski ischemic scale. The remaining clinical assessments are completed by a member of the research team and include physiology and blood sampling. If amyloid status is unknown, participants proceed to either cerebrospinal fluid examination or amyloid PET imaging according to participant preference and eligibility. For patients, where participants' amyloid status has been confirmed at any timepoint previously, a positive result enables participation, a negative result excludes participation.

One hundred people with mild cognitive impairment or Alzheimer's disease and 30 neurologically normal people proceed to baseline assessment. Participants undergo structured neuropsychological assessment, an M/EEG scan and MRI imaging of brain structure and function over two sessions (or three by preference).

We invite 30 people from the patient group (i.e. mild cognitive impairment or Alzheimer's disease) to repeat the M/EEG scan between two and four weeks after the first scan.

and =0.05. We expect <20% attrition.

. CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted May 18, 2021. Invitations are prioritised to people who can most readily attend the additional session (e.g. considering distance) until the target sample size is reached.

Participants in the patient group repeat the clinical and neuropsychological assessments, M/EEG scan, MRI scan and blood collection at 12 months after baseline.

Clinical and neuropsychological assessments are repeated at 24 months for participants in the patient group.

The timeline for the study is illustrated in Figure 3 .

Participants are asked to consume only water for two hours prior to blood collection. At baseline and follow-up, blood is drawn in the following order: 2.7ml in Sodium Citrate Tubes (plasma), 5ml in Serum Separator Tubes (serum), 10ml in an EDTA tube (DNA), 10ml in an EDTA tube (plasma and buffy coat) and 2.5ml in each of 2 PAXgene tubes (RNA). Once filled, the EDTA and PAXgene tubes are gently inverted 10 times. From April 2021, 4.9ml of blood is collected for SARS-CoV-2 serology. The samples are processed and frozen according to the guidelines for the constituents of interest in .

. CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted May 18, 2021. ; https://doi.org/10.1101/2021.05.18.21257340 doi: medRxiv preprint

Clinical criteria are insufficient to reliably diagnose the presence of Alzheimer's disease pathology. [35, 36] We seek additional biomarker evidence of the presence of Alzheimer's pathology, using either cerebrospinal fluid or PET imaging according to participant preference and eligibility. [37] Cerebrospinal fluid Cerebrospinal fluid is obtained by lumbar puncture and collected in polypropylene tubes. Within one hour of collection, the cerebrospinal fluid is centrifuged, separated and the supernatant frozen to −80°C for later batched analysis using a chemiluminescent enzyme immunoassay for total tau, phosphorylated tau and amyloid beta 1-42 levels. Positive amyloid status is indicated by a total tau to amyloid beta 1-42 ratio >1, and amyloid beta 1-42 concentration <450pg/ml.

Participants receive a 300 MBq bolus injection of florbetaben and are scanned 80-100 minutes post-injection on a GE Signa PET/MR scanner at the Wolfson Brain Imaging Centre, Cambridge or a GE D710 PET/CT scanner at the Churchill Hospital, Oxford. The centiloid method is used to classify the florbetaben scans as amyloid positive with centiloid >1.19. [38, 39] 

Clinical assessments are completed at a clinical research centre in one or two sessions.

A study clinician interviews the participant and study partner. The clinician follows a structured interview that covers socio-demographic factors, including age and years of

The sample in the sodium citrate tube is centrifuged at 2000g for 10 minutes at room temperature. The plasma is aliquoted into 1.4 ml matrix tubes and stored at -80°C.

At least 30 minutes after blood collection, the sample in the serum separator tube is centrifuged at 2000g for 10 min at room temperature. The serum is aliquoted into 1.4ml matrix tubes and stored at -80°C.

Similarly, the sample in the S-monovette tube is centrifuged at 2000g for 10 minutes at room temperature at least 30 minutes after collection. The sample is aliquoted into 2ml Sarstedt tubes.

The first EDTA tube is frozen as soon as possible and stored at -80°C for later DNA extraction and analysis.

The second EDTA tube is centrifuged immediately at 2500g for 15 minutes at room temperature. The plasma and buffy coat are aliquoted into separate 1.4 ml matrix tubes and stored at -80°C.

The Paxgene tubes are stored at room temperature for 2 hours before being frozen upright at -20°C for 24 hours and then stored at -80°C. is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted May 18, 2021. ;  education; lifestyle factors; family history of dementia; medical history, including information on significant medical conditions with date of onset; and concomitant medication usage, with details about dosage and duration.

The revised Addenbrooke's Cognitive Examination (ACE-R) evaluates orientation, memory, verbal fluency, language and visuo-spatial domains. [40] It is administered and scored according to the ACE-R Administration and Scoring Guide (2006) . Alternate versions at each visit reduce practice effects.

The Mini-Mental State Examination was acquired. [41] Clinical Dementia Rating The Clinical Dementia Rating quantifies the severity of dementia through a structured interview. [42] [43] [44] The interviewer rates participant impairments in 6 categories: memory, orientation, judgment and problem solving, community affairs, home and hobbies and personal care. The global CDR is derived from these ratings. [43] Haschinski Ischaemic Score The Rosen modification of Haschinski's Ischaemic Score seeks to differentiate between primary progressive dementias, including Alzheimer's disease and multi-infarct dementia. [45] A study clinician uses information from medical history, physical and neurological examination and medical records to determine the score. Scores below 4 indicate a low likelihood of vascular disease as the cause of dementia.

The participant completes the 30-item Geriatric Depression Scale,[46] 40-item Spielberger State-Trait Anxiety Inventory, [47] and 11-item Pittsburgh Sleep Quality Index. [48] The study partner completes the 30-item Amsterdam Instrumental Activity of Daily Living Questionnaire (short version) [49] and Mild Behavioral Impairment Checklist. [50] Physiological measures Height, weight, hip-waist ratio, blood pressure, pulse rate and temperature are measured for each participant using a stadiometer, electronic weight scales and stretch-resistant tape.

The neuropsychological test battery closely resembles the Deep and Frequent Phenotyping study [51] and IMI-European Prevention of Alzheimer's Disease, [52, 53] including the Pre-Alzheimer Cognitive Composite. [54] The assessments take place in a private, testing room in one session with breaks as needed (see Table 3 ).

. CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted May 18, 2021. ;

Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) measures cognitive decline in 5 domains: immediate memory, visuospatial, language, attention and delayed memory. [55] Participants receive alternate forms at repeated assessments. The immediate memory index comprises the list learning subtest, with immediate recall of 10items over 4 trials and the story memory subtest, with immediate recall of a 12-item story over two trials. The visuospatial index comprises the figure copy subtest, which involves copying a geometric figure and the 10-item, line orientation subtest. The language index comprises the 10-item, picture naming subtest and the semantic fluency subtest, where the participant must name as many exemplars of the given semantic category as they can in 60 seconds. The attention index comprises the digit span forwards subtest, involving immediate is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted May 18, 2021. ;  repetition of increasing digit strings and the coding subtest, scored as the total number of correctly coded numbers generated using an item-to-number code within 90 seconds. The delayed memory index comprises the list recall subtest, involving free recall of the list learning task; list recognition, where the participant decides whether a word was included in the list learning task; story recall, where the participant freely recalls the story memory task; and figure recall, where the participant draws from memory the figure presented in the figure copy task.

Digit span backwards, from the Wechsler adult intelligent scale, [56] is used in conjunction with RBANS digit span forwards. It follows the RBANS digit span format except that the participant is asked to immediately repeat in reverse order.

The Free and Cued Selective Reminding Testassesses episodic memory and distinguishes retrieval from storage deficits. [57] Sixteen pictured items are encoded during the initial learning phase, where the participant identifies and names items responding to unique semantic cues. After a short delay, the participant freely recalls all items. The interviewer prompts for each item not recalled using the unique semantic cues from the learning phase. Participants receive alternate forms at repeated assessments. This test forms part of the Pre-Alzheimer Cognitive Composite.

Logical Memory, taken from the third edition of the Wechsler memory scale, assesses episodic memory. [58] The participant immediately recalls short stories they have been read. After a 30-minute delay with intervening tests, the participant freely recalls the stories and answers yes or no questions that test story recognition. This test forms part of the Pre-Alzheimer Cognitive Composite.

The national adult reading test (second edition) estimates premorbid intelligence, [59] from printed irregular words.

The digit symbol substitution from the Wechsler Adult Intelligence Scale assesses processing speed and attention. [56] The participant has 90 seconds to code as many correct symbols as possible corresponding to presented numbers by using the given number-to-symbol code. This test forms part of the Pre-Alzheimer Cognitive Composite.

The Trails Making Test B assesses executive function, attention and processing speed. [60] Following a practice sample to ensure the participant understands the task, the participant is presented with the test comprising 25 encircled numbers which they must connect by alternating between numbers and letters. The time it takes to complete the sample and any errors made are recorded.

The tablet-based Cambridge Neuropsychological Test Automated Battery test battery assesses processing speed, episodic memory, attention, working memory and executive . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted May 18, 2021. ; https://doi.org/10.1101/2021.05.18.21257340 doi: medRxiv preprint function. [61] The reaction time task (simple and five choice variant) assesses processing speed. The participant holds down a response button and must release this to respond to a target on screen. The paired associates learning task (standard variant) assesses episodic memory. The participant learns associations between patterns and their locations. There is an initial learning stage followed by immediate recall. The rapid visual processing task (3 target variant) assesses attention. Single digits appear on the screen and the participant responds when they see a string matching the target sequences. The spatial working memory task (standard variant) assesses working memory and executive function. The participant searches inside multiple boxes on the screen to find and collect tokens. Tokens do not appear in the same box twice.

The tablet-based four mountains task assesses allocentric spatial processing.

[62] During a learning phase of each trial, the participant learns the topographical layout of 4 mountains presented in a computer-generated landscape. Following a delay, the participant is presented with four alternative images and must identify the target image that matches the topographical mountain layout of the image presented in the learning phase of the trial, but with potentially altered colours, textures and points of view. The position of the standard fiducial points, >300 additional head points, five head position indicator coils and the EEG electrodes are recorded using the Polhemus digitisation system. The head position indicator coils measure head position within the MEG helmet. Three pairs of bipolar electrodes record electrocardiogram data, with electrodes placed on the right clavicle and left lower rib, and vertical and horizontal electrooculogram data, with electrodes placed above the left eyebrow, below the left eye and lateral canthus of each eye. A reference electrode is placed on the left side of the nose and a ground electrode is placed on the left cheek. During the seated scan, the participant rests or performs simple task using a button box to respond. The participant wears non-magnetic earphones with sound delivered though plastic tubes and, if necessary, non-magnetic glasses. Prior to M/EEG a Snellen eye test and pure tone audiometry assess sight and hearing thresholds. The tasks are carried out in the following order for each M/EEG session. The study will identify a harmonised MEG/EEG pre-processing pipeline, to be confirmed before baseline data acquisition is completed. Simple audio-visual task

The participant fixates on a red central fixation dot and responds each time an auditory or visual stimulus is presented (see Figure 4a ). Auditory tones (n=100) of 300, 600 or 1200Hz frequency are presented for 300-ms duration after a blank interval of 1000ms. Visual stimuli are concentric black and white circles that appear for 300ms after 3000ms. Participants respond as quickly as possible after detecting a stimulus. Filler trials (n=30) containing only the red fixation dot are also included. Visual and auditory trials are randomly interspersed. Ten initial practice trials are also included to familiarise participants to the task.

. CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted May 18, 2021. ;

The roving auditory mismatch negativity task is designed to elicit error responses to novel, deviant tones followed by rapid plasticity as predictions are updated upon repetition of the deviant stimulus. [63, 64] The participant passively watches a muted nature documentary. Through earpieces, they hear binaural, in-phase sinusoidal tones >60dB above the average auditory threshold with a duration of 100ms and stimulus onset asynchrony of 500ms. The frequency of each tone is the same within a block but different between the blocks. Blocks range from 400 to 800 Hz. The number of tones per blocks varies from 3 to 11, according to a truncated exponential distribution. The first tone of each block is called a deviant tone and the sixth repetition is called a standard tone (see Figure 4b ).

In this passive memory test, participants view a series of complex scenes (landscapes and cityscapes) and press a button only when they see a scene containing a moon (n=26, different moon images). Target scenes containing a moon require participants to attend to every scene but are not of interest; the main interest is the difference between initial and repeated presentation of the non-target scenes. Each scene is presented for 800ms and preceded by a fixation cross presented for 200ms on average (100-300ms). Scenes are pseudo-randomly intermixed with the constraint that there are 10 initial 'burn-in' complex scenes with 2 moon target scenes, followed by 256 complex scenes presented twice with 14-93 (median=42) intervening scenes between the first and repeat presentation (see Figure 4c ).

The task assesses hippocampal-dependent paired associates learning. [65, 66] The trials comprise a visual abstract "object" for 700ms and a sound presented for 400ms, starting 300ms after trial onset. The inter-stimulus interval averages 300ms. During the initial training period (80 trials), participants learn the association between four standard pairs of visual objects and sounds. The main task consists of 770 bimodal trials and 40 unimodal, target trials. The trials are randomly intermixed. The bimodal trials consist of: the standard, learnt pairs of objects and sounds (n=670); standard objects paired with a novel sound (n=50); and mismatched object-sound pairs, where the sound from a pre-learnt, standard pair is presented with an object from a different learnt, standard pair (n=50). For unimodal trials, the participant presses a button when they see a fifth visual object (the letter 'a', see Figure 4d ) which ensures the task is attended. The task is followed by a 10-item assessment in which a standard sound is presented and the participant reports which of four presented objects the sound was paired with most often during the task.

The participant is presented with a small central fixation cross and is given the following instructions: 'In the next 5 minutes, we will do a recording as you rest. Please clear your mind, relax, and try not to think of anything in particular. Please stay awake and focus your eyes on the cross at the centre of the screen'.

The participant is given the following instructions: 'In the next 5 min, we will do a recording as you rest. Please clear your mind, relax, and try not to think of anything in particular. Please close your eyes but do not fall asleep.' . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted May 18, 2021. is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) 

The MRI sequences use 3T Siemens PRISMA scanners, at the MRC Cognition and Brain Science Unit, Cambridge, and the Oxford Centre for Human Brain Activity, Oxford. The sequences in order of acquisition are: localiser, T1-weighted, T2 Fluid Attenuated Inversion Recovery (FLAIR), T2*-weighted, T2-weighted with fat saturation, diffusion weighted imaging, quantitative susceptibility mapping, resting state eyes open, hippocampal subfields, and 3D arterial spin labelling. Details of the sequences are in Table 4 . 

For the resting-state scan, the participant is presented with a fixation cross and asked to maintain fixation throughout the task. Echo planar images are acquired with 200 volumes with the following parameters: TE=30.00ms, TR=1500.00ms, flip angle =90 degrees, acquisition matrix =64x64, number of slices =54, slice thickness =3.00mm, voxel size = 3.00mm isotropic, acquisition time =5 minutes 50 seconds

The high-resolution, hippocampal subfield images are acquired with T2weighted, turbo spin echo sequences and run with the following parameters: TE=50.00ms, TR=8020.00ms, flip angle =122 degrees, acquisition matrix =448x448, number of slices =30, slice thickness =2.00mm, voxel size =0.4x0.4x2.0mm, acquisition time =8 minutes 11 seconds.

3D Arterial Spin Labelling images are acquired using a flow-sensitive alternating inversion recovery spin-echo pulsed sequence with Q2-TIPS bolus saturation in the transverse plane with the following parameters: TR=4000.00ms; TE =13.20ms; flip angle =130 degrees, labelling duration =800ms, post-labelling delay =2000ms, acquisition matrix =64x60; slices per slab =32, slice thickness =4.50mm, voxel size =1.85x1.85x4.50mm, acquisition time =6 minutes 46 seconds. 

The study is currently active at both sites.

The study has received a favourable opinion from the East of England -Cambridge Central Research Ethics Committee (REC reference 18/EE/0042). Imaging data and clinical severity scores are hosted by the Dementias Platform UK Imaging Platform (https://portal.dementiasplatform.uk), using XNAT technology (https://www.xnat.org). The data will be made available by a managed access process through the DPUK, subject to constraints to preserve confidentiality and privacy.

With a pressing need to evaluate new treatments for Alzheimer's disease, measures that are sensitive to changes in the underlying neurophysiology of the human disease are needed. The NTAD study establishes a dataset that will allow detailed assessment of neurophysiological measures of annual progression, linked to cognitive and MRI changes and baseline blood and DNA. The unique design of the NTAD study enables an assessment of MEG as a potential biomarker in Alzheimer's disease intervention trials.

Animal models of Alzheimer disease

Alzheimer's disease: experimental models and reality

Alzheimer's disease drug-development pipeline: Few candidates, frequent failures

Reasons for failed trials of disease-modifying treatments for alzheimer disease and their contribution in recent research

Why do so many clinical trials of therapies for Alzheimer's disease fail?

Why do trials for Alzheimer's disease drugs keep failing?

The clinical use of structural MRI in Alzheimer disease

Unbiased comparison of sample size estimates from longitudinal structural measures in ADNI

Automated cross-sectional and longitudinal hippocampal volume measurement in mild cognitive impairment and Alzheimer's disease

Tau burden and the functional connectome in Alzheimer's disease and progressive supranuclear palsy

PK11195 binding in Alzheimer disease and progressive supranuclear palsy

18F-AV-1451 positron emission tomography in Alzheimer's disease and progressive supranuclear palsy

Tau PET imaging in neurodegenerative tauopathies-still a challenge

Tau PET patterns mirror clinical and neuroanatomical variability in Alzheimer's disease

Neuroimaging of inflammation in memory and related other disorders (NIMROD) study protocol: A deep phenotyping cohort study of the role of brain inflammation in dementia, depression and other neurological illnesses

Alzheimer's disease: Synapses gone cold

Amyloid-Β-induced neuronal dysfunction in Alzheimer's disease: From synapses toward neural networks

Synapse loss and progress of Alzheimer's disease -A network model

Meta-analysis of synaptic pathology in Alzheimer's disease reveals selective molecular vesicular machinery vulnerability

Synapse loss in the prefrontal cortex is associated with cognitive decline in amyotrophic lateral sclerosis

Pathological tau disrupts ongoing network activity

Dynamic causal modelling of lateral interactions in the visual cortex

GABA-ergic dynamics in human frontotemporal networks confirmed by pharmaco-magnetoencephalography

Neurophysiological signatures of Alzheimer's disease and frontotemporal lobar degeneration: pathology versus phenotype

Short timescale abnormalities in the states of spontaneous synchrony in the functional neural networks in Alzheimer's disease

Alterations in resting-state network dynamics along the Alzheimer's disease continuum

Biomagnetic biomarkers for dementia: A pilot multicentre study with a recommended methodological framework for magnetoencephalography

Magnetoencephalography of frontotemporal dementia: Spatiotemporally localized changes during semantic decisions

Reorganization of cortical oscillatory dynamics underlying disinhibition in frontotemporal dementia

Improving response inhibition systems in frontotemporal dementia with citalopram

The impact of neurodegeneration on network connectivity: A study of change detection in frontotemporal dementia

Loss of EEG Network Efficiency Is Related to Cognitive Impairment in Dementia With Lewy Bodies

Statistical power analyses using G*Power 3.1: Tests for correlation and regression analyses

Prevalence of Amyloid PET Positivity in Dementia Syndromes: A Meta-analysis HHS Public Access

Characterizing apolipoprotein E ε4 carriers and noncarriers with the clinical diagnosis of mild to moderate Alzheimer dementia and minimal β-amyloid peptide plaques

The diagnosis of dementia due to Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease

Florbetaben PET imaging to detect amyloid beta plaques in Alzheimer's disease: Phase 3 study

18F-Florbetaben PET beta-amyloid binding expressed in Centiloids

The Addenbrooke's Cognitive Examination revised (ACE-R): A brief cognitive test battery for dementia screening

Mini-mental state'. A practical method for grading the cognitive state of patients for the clinician

A new clinical scale for the staging of dementia

The clinical dementia rating (cdr): Current version and scoring rules

Pathological verification of ischemic score in differentiation of dementias

Manual for the State-Trait Anxiety Inventory

The Pittsburgh sleep quality index: A new instrument for psychiatric practice and research

Detecting functional decline from normal aging to dementia: Development and validation of a short version of the Amsterdam IADL Questionnaire

The Mild Behavioral Impairment Checklist (MBI-C): A Rating Scale for Neuropsychiatric Symptoms in Pre-Dementia Populations

Deep and Frequent Phenotyping study protocol: an observational study in prodromal Alzheimer's disease

European Prevention of Alzheimer's Dementia Longitudinal Cohort Study (EPAD LCS): Study protocol

Recommended cognitive outcomes in preclinical Alzheimer's disease: Consensus statement from the European Prevention of Alzheimer's Dementia project

The preclinical Alzheimer cognitive composite: Measuring amyloid-related decline

The Repeatable Battery for the Assessment of Neuropsychological Status (RBANS): Preliminary clinical validity

Wechsler Adult Intelligence Scale -Revised

Temporal unfolding of declining episodic memory on the Free and Cued Selective Reminding Test in the predementia phase of Alzheimer's disease: Implications for clinical trials

Wechsler Memory Scale -Third UK Edition. London: Harcourt Assessment

National Adult Reading Test (NART): Test Manual

Administration and interpretation of the Trail Making Test

Cambridge Cognition. CANTAB® [Cognitive assessment software

The hippocampus is required for short-term topographical memory in humans

Dynamic causal modelling of evoked responses: The role of intrinsic connections

A theory of cortical responses

Hippocampal dysfunction in patients with mild cognitive impairment: A functional neuroimaging study of a visuospatial paired associates learning task

Detecting dementia: Novel neuropsychological markers of preclinical Alzheimer's disease

MRtrix3: A fast, flexible and open software framework for medical image processing and visualisation